Survodutide shows promising results in Phase 2 study for weight loss in obese people
Boehringer Ingelheim and Zealand Pharma have announced further data showcasing the superior efficacy of survodutide (BI 456906) compared to placebo in individuals with overweight or obesity without type 2 diabetes after 46 weeks of treatment. The Phase II study included two analyses: planned and actual dose. Participants who completed the study on the 4.8 mg […]